The pharmaceutical industry wasn’t directly represented at the White House’s pharmacy benefits management roundtable on 4 March, but their agenda – to put the onus of drug affordability challenges on PBMs – took center stage, offered by actors who likely make the industry’s messages more palatable.
The big three PBMs, as they were called during the discussion titled to “bring transparency to prescription drug middlemen,” weren’t...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?